Dashboard
Manage Tickers

CLARClarus Corp

Nasdaq claruscorp.com


$ 4.93 $ -0.80 (-13.86 %)    

Friday, 02-Aug-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 427.00 $ 0.00 (0 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 4.97
$ 4.94 x 100
-- x --
-- - --
$ 4.71 - $ 9.26
1,177,954
na
190.34M
$ 0.99
$ 28.25
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-01-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-01-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-07-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-02-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-08-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-09-2020 12-31-2019 10-K
20 11-04-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-06-2019 03-31-2019 10-Q
23 03-04-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-06-2017 12-31-2016 10-K
32 10-31-2016 09-30-2016 10-Q
33 08-01-2016 06-30-2016 10-Q
34 05-02-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-04-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

roth-mkm-downgrades-clarus-to-neutral-lowers-price-target-to-6
Roth MKM Downgrades Clarus to Neutral, Low...
08/02/2024 17:03:10

Roth MKM analyst Matt Koranda downgrades Clarus (NASDAQ:CLAR) from Buy to Neutral and lowers the price target from $7.5 to $6.

clarus-sees-fy24-revenue-270m-280m-vs-27831m-est
Clarus Sees FY24 Revenue $270M-$280M Vs $2...
08/01/2024 21:41:19

2024 OutlookThe Company continues to expect fiscal year 2024 sales to range between $270 million to $280 million. Due to invest...

clarus-q2-2024-adj-eps-003-misses-001-estimate-sales-56484m-miss-58536m-estimate
Clarus Q2 2024 Adj. EPS $(0.03) Misses $(0...
08/01/2024 20:39:03

Clarus (NASDAQ:CLAR) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 2...

b-riley-securities-maintains-buy-on-clarus-raises-price-target-to-9
B. Riley Securities Maintains Buy on Claru...
05/06/2024 17:30:44

B. Riley Securities analyst Anna Glaessgen maintains Clarus (NASDAQ:CLAR) with a Buy and raises the price target from $8 to $9.

12-consumer-discretionary-stocks-moving-in-fridays-intraday-session
12 Consumer Discretionary Stocks Moving In...
05/03/2024 16:31:53

clarus-sees-fy24-revenue-270m-280m-vs-27562m-est
Clarus Sees FY24 Revenue $270M-$280M Vs $2...
05/02/2024 21:53:11

2024 OutlookThe Company continues to expect fiscal year 2024 sales to range between $270 million to $280 million and adjusted E...

clarus-q1-sales-69311m-beat-64333m-estimate
Clarus Q1 Sales $69.311M Beat $64.333M Est...
05/02/2024 21:29:55

Clarus (NASDAQ:CLAR) reported quarterly sales of $69.311 million which beat the analyst consensus estimate of $64.333 million b...

roth-mkm-maintains-buy-on-clarus-raises-price-target-to-75
Roth MKM Maintains Buy on Clarus, Raises P...
03/13/2024 14:35:43

Roth MKM analyst Matt Koranda maintains Clarus (NASDAQ:CLAR) with a Buy and raises the price target from $6.5 to $7.5.

12-consumer-discretionary-stocks-moving-in-wednesdays-pre-market-session
12 Consumer Discretionary Stocks Moving In...
03/13/2024 13:06:08

thursday-is-your-last-chance-to-buy-clarus-before-the-dividend-payout
Thursday Is Your Last Chance To Buy Clarus...
03/12/2024 14:45:43

clarus-files-lawsuit-against-caption-management-llc-caption-partners-ii-lp-caption-gp-llc-william-cooper-and-jason-strasser-for-recovery-of-short-swing-profits
Clarus Files Lawsuit Against Caption Manag...
03/11/2024 11:29:46

12-consumer-discretionary-stocks-moving-in-fridays-intraday-session
12 Consumer Discretionary Stocks Moving In...
03/08/2024 17:31:12

lake-street-maintains-buy-on-clarus-lowers-price-target-to-6
Lake Street Maintains Buy on Clarus, Lower...
03/08/2024 15:57:58

Lake Street analyst Mark Smith maintains Clarus (NASDAQ:CLAR) with a Buy and lowers the price target from $7 to $6.

clarus-board-of-directors-approves-two-top-shareholders-to-increase-their-positions-up-to-15-and-267-of-shares-outstanding
Clarus Board of Directors Approves Two Top...
03/08/2024 11:58:32

clarus-expects-fy24-net-sales-270m-280m
Clarus Expects FY24 Net Sales $270M-$280M
03/07/2024 21:59:35

clarus-q4-earnings-insights
Clarus: Q4 Earnings Insights
03/07/2024 21:50:18

clarus-q4-2023-adj-eps-0070-misses-0090-estimate-sales-76503m-miss-84487m-estimate
Clarus Q4 2023 Adj EPS $(0.070) Misses $0....
03/07/2024 21:48:12

Clarus (NASDAQ:CLAR) reported quarterly losses of $(0.070) per share which missed the analyst consensus estimate of $0.090 by 1...

b-riley-securities-maintains-buy-on-clarus-lowers-price-target-to-8
B. Riley Securities Maintains Buy on Claru...
03/07/2024 13:15:15

B. Riley Securities analyst Anna Glaessgen maintains Clarus (NASDAQ:CLAR) with a Buy and lowers the price target from $9 to $8.

earnings-scheduled-for-march-7-2024
Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

jefferies-downgrades-clarus-to-hold-lowers-price-target-to-7
Jefferies Downgrades Clarus to Hold, Lower...
01/04/2024 13:07:04

Jefferies analyst Randal Konik downgrades Clarus (NASDAQ:CLAR) from Buy to Hold and lowers the price target from $13 to $7.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)